• Publications
  • Influence
IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer
Serine/threonine kinase IKBKE is a newly identified oncogene; however, its regulation remains elusive. Here, we provide evidence that IKBKE is a downstream target of signal transducer and activatorExpand
  • 59
  • 4
A small-molecule E2F inhibitor blocks growth in a melanoma culture model.
HLM006474 was identified using a computer-based virtual screen and the known crystal structure of the DNA-bound E2F4/DP2 heterodimer. Treatment of multiple cell lines with HLM006474 resulted in theExpand
  • 60
  • 2
  • PDF
Tripartite Motif Containing 28 (Trim28) Can Regulate Cell Proliferation by Bridging HDAC1/E2F Interactions*
Background: Trim28 appears up-regulated in many cancers. Results: In early stage lung tumors high Trim28 correlates with increased overall survival and Trim28 reduces cell proliferation in model lungExpand
  • 62
E2F Inhibition Synergizes with Paclitaxel in Lung Cancer Cell Lines
The CDK/Rb/E2F pathway is commonly disrupted in lung cancer, and thus, it is predicted that blocking the E2F pathway would have therapeutic potential. To test this hypothesis, we have examined theExpand
  • 22
Early2 factor (E2F) deregulation is a prognostic and predictive biomarker in lung adenocarcinoma
Clinicians routinely prescribe adjuvant chemotherapy (ACT) for resected non-small cell lung cancer patients. However, ACT only improves five-year disease-free survival in stage I-III non-small cellExpand
  • 2
  • PDF
Abstract 3255: IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer
Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL Serine/threonine kinase IKBKE is a newly identified oncogene, however, its regulation remains elusive. Here, we provideExpand
Abstract 914: Development of a prognostic and predictive E2F signature in formalin-fixed, paraffin-embedded early-stage non-small cell lung cancer samples
Lung cancer remains the leading cause of cancer-related death in the United States. The 5 year survival for stage I-IIIA lung cancer ranges from only 15-50%. For many in the early stages of theExpand
Novel Therapeutic Strategies in Lung Cancer
Lung cancer is the leading cause of cancer-related death and the second most diagnosed cancer in the United States. Unfortunately, many patients either do not have any common mutations for whichExpand
Abstract 2354: An E2F signature predicts benefit of adjuvant chemotherapy in early-stage non-small cell lung cancer.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Early-stage non-small cell lung cancer (NSCLC) is primarily treated by surgical resection. Unfortunately, after resection,Expand
Abstract 2943: Targeting the E2F pathway in cancer chemotherapeutics
HLM006474 is a recently identified small molecule E2F inhibitor. Since E2F is known to drive expression of genes required for cell cycle progression, it is predicted that blocking the E2F pathwayExpand